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Atrial  ﬁbrillation  (AF),  the  most  common  cardiac  arrhythmia,  is  complex  to  manage  because
it  is  associated  with  many  other  morbid  conditions  and  complications.  The  most  severe
complication  of  AF  is  ischaemic  stroke,  the  third  most  frequent  cause  of  death  and  the
leading  cause  of  serious  disability  worldwide.  AF  is  one  of  the  main  causes  of  ischaemic
stroke,  being  responsible  for  one  in  ﬁve  cases  [1].
Owing  to  the  incidence  and  severity  of  ischaemic  stroke,  its  prophylaxis  is  a  crucial
component  of  AF  management.  Stroke  risk  assessment  scores  such  as  the  CHADS2 [2]  and
the  CHA2DS2-VASc  [3]  scores  have  been  developed  to  assess  the  risk  of  thromboembolicAtrial  ﬁbrillation events  and  to  determine  whether  a  patient  with  AF  should  receive  anticoagulation.  If  the
CHA2DS2-VASc  score  is  2  or  more,  then  oral  anticoagulation  is  ﬁrmly  recommended.  Some
patients  with  a  score  of  1  should  also  receive  anticoagulation,  but  this  is  recommended  on
an  individual  basis  [4].
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Despite  the  proven  efﬁcacy  of  anticoagulation  with  both
arfarin  and  recently  available  non-vitamin  K  oral  anticoag-
lants  (NOACs),  there  is  much  reluctance  to  start  patients
n  anticoagulation  for  fear  of  bleeding  complications.  Epi-
emiological  studies  have  shown  that  more  than  one-third
f  patients  with  AF  who  are  eligible  for  anticoagulation
CHA2DS2-VASc  score  ≥  2)  continue  to  be  managed  subop-
imally  with  no  anticoagulation  or  with  only  antiplatelet
gents,  presumably  because  of  an  overinﬂated  perception
f  their  risk  of  bleeding  [5].
It  is  estimated  that  90%  of  all  cardiac  clots  that  form
uring  AF  are  localized  to  the  left  atrial  appendage  (LAA)
6].  As  a  result,  LAA  surgical  ligation  or  mechanical  occlu-
ion  has  emerged  since  1930  as  a  potential  alternative
o  oral  anticoagulation  (OAC)  to  reduce  the  risk  of  AF-
elated  stroke  without  a  concomitant  increase  in  bleeding
isk  [7].  In  2005,  two  entirely  catheter-based  devices,  the
mplatzer  Cardiac  Plug  (ACP)  and  the  second-generation
MULET  device  (St  Jude  Medical),  were  approved  in  Europe.
n  March  2015,  the  US  Food  and  Drug  Administration  (FDA)
gency  ﬁnally  approved  the  Watchman  left  atrial  appendage
losure  (LAAC)  device  (Boston  Scientiﬁc)  for  the  US  market,
fter  multiple  reviews  by  FDA  committees,  starting  in  2010.
he  aim  of  this  device  is  to  reduce  the  risk  of  LAA-mediated
hromboembolism  in  patients  who  are  not  candidates  for
hronic  anticoagulation.
The  most  comprehensive  and  long-term  evaluation  of
he  Watchman  LAAC  device  was  published  by  Holmes  et  al.
8].  This  patient-level  meta-analysis  of  the  PROTECT  AF  [9]
nd  the  PREVAIL  [10]  randomized  controlled  trials  and  their
espective  registries,  CAP  and  CAP2  [11],  includes  data  on
877  patients  treated  with  the  Watchman  device  and  382
ontrol  patients  treated  with  long-term  warfarin,  totalling
931  patient-years  of  follow-up.  These  data  demonstrated
hat  the  LAAC  device  provides  similar  beneﬁts  to  warfarin  for
educing  the  composite  efﬁcacy  endpoint  of  stroke,  systemic
mbolism  or  cardiovascular  death.  However,  on  detailed
nalysis,  ischaemic  strokes  were  more  frequent  in  the  device
roup  (1.6  vs.  0.9  events  per  100  patient-years;  hazard  ratio
.95;  P  =  0.05),  whereas  haemorrhagic  strokes  occurred  less
requently  in  the  device  group  (0.15  vs.  0.22  events  per  100
atient-years;  hazard  ratio  0.22;  P  =  0.004).  The  authors  also
ound  a  52%  reduction  in  cardiovascular  death  in  patients
reated  with  the  Watchman  device  compared  with  warfarin
1.1  vs.  2.3  events  per  100  patient-years;  P  =  0.006).
Even  if  the  conclusion  of  this  meta-analysis  [8]  is  encour-
ging,  presenting  the  LAAC  technique  as  safe,  effective  and
referable  to  chronic  OAC  therapy,  OAC  and  NOACs  remain
he  ﬁrst-line  therapy  for  thromboembolic  prophylaxis  in  non-
alvular  AF.  The  LAAC  device  should  not  yet  be  considered
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s  superior  treatment  because  randomized  data  are  cur-
ently  limited  to  only  two  studies  with  the  Watchman
evice  [9,10]  comparing  it  only  to  a  single  agent  (war-
arin),  and  the  ACP/AMULET  data  are  based  exclusively
n  observational  studies.  It  is  uncertain,  for  example,
ow  the  LAAC  device  will  perform  when  compared  with
OACs.
The  European  Heart  Rhythm  Association  (EHRA)/
uropean  Association  of  Percutaneous  Cardiovascular  Inter-
entions  (EAPCI)  [12]  expert  consensus  statement  on
atheter-based  LAA  occlusion  and,  more  recently,  the  expert
onsensus  statement  established  by  the  Rhythm  and  Car-
iac  Pacing  and  the  Atheroma  and  Interventional  Cardiology
roups  (GACI)  of  the  French  Society  of  Cardiology  [13],
ecommend  that  OAC  currently  remains  the  standard  of
herapy  for  eligible  patients.  They  deﬁned  patients  with  high
hromboembolic  risk  (CHA2DS2-VASc  score  ≥  2)  and  a  chronic
ontraindication  for  anticoagulation  as  possible  candidates
or  LAAC,  while  the  French  Health  Authority  (Haute  Autorité
e  santé)  recommends  LAAC  only  for  patients  with  very  high
hromboembolic  risk  (CHA2DS2-VASc  score  ≥  4)  with  a  for-
al  contraindication  for  oral  anticoagulation.  Even  though
hese  restrictions  on  patient  selection  seem  to  be  the  most
urrently  accepted  clinical  indication  for  LAA  occlusion,  no
andomized  data  targeting  this  speciﬁc  group  of  patients
re  yet  available.  On  further  analysis,  we  can  conclude
hat  the  European  statements  and  FDA  approval  are  actu-
lly  based  solely  on  expert  consensus  because  the  only
andomized  controlled  trials  available  (PROTECT  AF  and
REVAIL  [9,10])  excluded  patients  ineligible  for  oral  anti-
oagulation:  in  ﬁne  the  speciﬁc  population  deﬁned  in  the
tatement.  An  important  point  of  these  statements  is  the
rocedural  environment.  The  EAPCI  recommends  that  in
he  case  of  severe  complications,  the  maximum  transfer
ime  to  a  cardiac  surgery  facility  must  be  no  longer  than
0  minutes.  In  contrast,  the  statement  edited  by  the  two
roups  of  the  French  Society  of  Cardiology  [13]  and  the
dvice  issued  by  the  French  Health  Authority  both  under-
ine  the  need  for  centres  to  offer  heart  surgery  backup  at
he  cathlab  site,  to  manage  catastrophic  cardiac  tampon-
des  and  device  embolization,  if  necessary.  At  this  stage
f  development  of  the  technique,  these  restrictions  appear
o  be  a  call  for  common  sense  and  restraint.  One-hour
ransportation  in  these  difﬁcult  clinical  conditions  would
robably  prove  fatal  to  patients.  Currently,  all  efforts  should
e  made  to  not  unnecessarily  increase  patient  risk.  If,  in
he  next  few  years,  all  implant  centres  gain  full  experi-
nce  and  if  the  procedural  risk  appears  more  acceptable
nd  the  patient  indications  extended,  this  position  could  be
evised.
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A  crucial  element  of  these  recommendations  is  to  deter-
mine  which  patients  are  eligible  for  LAAC  (i.e.  patients  with
a  chronic  contraindication  for  anticoagulation).  As  an  exam-
ple,  intracranial  haemorrhage  (ICH)  is  the  most  frequent
contraindication  for  anticoagulation  in  patients  with  AF,  rep-
resenting  about  60%  of  contraindicated  patients  [14].  ICH  is
the  second  most  common  subtype  of  stroke  and  accounts
for  approximately  20%  of  all  strokes,  thus  ICH  patients  may
represent  a  large  population  potentially  eligible  for  LAAC.
However,  it  is  important  to  establish  which  of  these  patients
have  a  chronic  and  formal  contraindication  for  anticoagula-
tion.  Among  ICHs,  lobar  ICHs  have  a  high  risk  of  recurrence
because  they  are  associated  with  cerebral  amyloid  angiopa-
thy,  an  incurable  neurodegenerative  disease,  whereas  deep
ICHs  are  mostly  induced  by  chronic  hypertension,  so  blood
pressure  control  can  reduce  their  risk  of  recurrence.  For
these  reasons,  North  American  guidelines  recommend  avoid-
ance  of  long-term  anticoagulation  after  warfarin-associated
spontaneous  lobar  ICH,  while  anticoagulation  after  deep  ICH
might  be  considered  [15].  In  the  future,  we  may  anticipate
that  patients  with  lobar  ICH  would  be  eligible  for  LAAC,
whereas  NOACs  versus  LAAC  should  be  discussed  for  patients
with  deep  ICH.  This  kind  of  discussion  about  ICH  patients
should  be  also  performed  for  gastrointestinal  bleedings,
haematological  disorders  and  geriatric  patients  in  order  to
deﬁne  the  right  population  for  LAAC.
Another  important  and  pragmatic  issue  is  the  post-
procedural  management  of  antithrombotic  therapy  in
patients  ineligible  for  oral  anticoagulation.  Indeed,  in  the
PROTECT  AF  and  PREVAIL  trials,  contraindication  for  war-
farin  was  an  exclusion  criterion  and  all  Watchman-implanted
patients  were  required  to  take  warfarin  for  at  least  45
days  after  implantation.  Just  a  small,  non-randomized  trial
(Aspirin  Plavix  Registry)  reported  the  Watchman  experience
in  150  patients  who  were  not  eligible  for  long-term  antico-
agulation,  demonstrating  a  reasonable  safety  proﬁle  over
short-term  follow-up  [16].  Even  these  patients,  however,
were  treated  with  6  months  of  dual  antiplatelet  therapy  fol-
lowed  by  lifelong  aspirin.  However,  dual  antiplatelet  therapy
increases  haemorrhagic  risk  and  recently  has  been  asso-
ciated  with  severe  ICH  after  device  implantation  [17,18].
A  large  clinical  trial  has  also  demonstrated  twice  as  fre-
quent  major  bleeding  with  dual  antiplatelet  therapy  than
with  aspirin  alone,  especially  for  intracranial  bleeding  (0.4%
vs.  0.2%  per  year,  respectively;  relative  risk  1.87;  95%  conﬁ-
dence  interval  1.19—2.94;  P  =  0.006)  [16].  The  absence  of
consensus  concerning  appropriate  antithrombotic  regimens
after  implantation  in  very  high  bleeding  risk  patients  such
as  ICH  patients  should  lead  to  well-designed  registries  and  a
randomized  study  to  establish  the  post-procedural  optimal
strategy.
In  conclusion,  we  believe  that  while  LAAC  appears
promising,  the  scarcity  of  randomized  data  combined  with
issues  regarding  patient  eligibility  deﬁnitions  in  the  only
randomized  trials  currently  undertaken  should  temper  any
overenthusiasm  for  LAAC.  Although  LAAC  appears  to  be
safe,  effective  and  preferable  to  chronic  OAC  therapy  for
thromboembolic  prophylaxis  in  non-valvular  AF,  the  current
indications  should  be  limited  to  patients  with  AF  who  are
at  a  very  high  risk  of  stroke  and  have  clear  contraindica-
tions  for  any  form  of  anticoagulation.  The  place  of  NOACs
in  this  treatment  strategy  remains  to  be  updated,  when
[ry  claims  require  evidence.  .  . 615
he  data  on  NOACs  in  patients  with  previous  ICH  become
vailable  [19].  Single  antiplatelet  therapy  with  aspirin  dur-
ng  device  endothelialization,  followed  (or  not)  by  lifelong
spirin,  depending  on  the  patient’s  vascular  risk,  might  be
onsidered  for  patients  with  a  formal  contraindication  for
AC  and  in  the  absence  of  randomized  controlled  trial  data.
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